Renal Modification of Metformin
Discontinue metformin when eGFR falls below 30 mL/min/1.73 m², halve the dose when eGFR is 30-44 mL/min/1.73 m², and do not initiate metformin if eGFR is below 45 mL/min/1.73 m². 1, 2
eGFR-Based Dosing Algorithm
eGFR ≥60 mL/min/1.73 m²
- Continue full dose without adjustment
- Start with 500 mg or 850 mg once daily (immediate-release) or 500 mg daily (extended-release)
- Titrate upward by 500 mg/day or 850 mg/day every 7 days until maximum dose (2550 mg/day for immediate-release, typically 2000 mg/day for extended-release)
- Monitor kidney function at least annually 1, 2
eGFR 45-59 mL/min/1.73 m²
- Continue same dose in most patients
- Consider dose reduction in certain high-risk conditions (acute illness, dehydration, contrast procedures)
- Increase monitoring frequency to every 3-6 months
- Do not initiate metformin in this range 1
eGFR 30-44 mL/min/1.73 m²
- Halve the current dose (e.g., if on 2000 mg/day, reduce to 1000 mg/day)
- Maximum recommended dose: 1000 mg/day
- Do not initiate metformin if patient is not already taking it
- Monitor kidney function every 3-6 months
- Provide sick-day education about temporary discontinuation during acute illness 1, 2
eGFR <30 mL/min/1.73 m²
- Stop metformin immediately
- Do not initiate under any circumstances
- Metformin is contraindicated at this level of kidney function
- Switch to alternative glucose-lowering agents (GLP-1 RA, insulin, DPP-4 inhibitors with appropriate dose adjustment) 1, 2
Critical Monitoring Requirements
Increase monitoring frequency when eGFR <60 mL/min/1.73 m² from annual to every 3-6 months. This is essential because patients with eGFR 30-45 mL/min/1.73 m² face increased risk of periodic drops to ≤30 mL/min/1.73 m², which heightens lactic acidosis risk 3, 1.
Contrast Media Procedures
Discontinue metformin during iodinated contrast procedures if:
- eGFR is 30-60 mL/min/1.73 m²
- History of liver disease, alcoholism, or heart failure
- Intra-arterial contrast administration planned
Stop metformin on the day of the procedure and hold for 48 hours post-procedure. Re-evaluate eGFR at 48 hours; restart only if renal function is stable 2, 4.
Additional Safety Considerations
Vitamin B12 Monitoring
Monitor vitamin B12 levels periodically, especially after 4 years of continuous metformin use. Metformin is associated with increased risk of vitamin B12 deficiency and potential worsening of neuropathy symptoms 3, 1, 5.
Very Elderly Patients (>78 years)
Exercise heightened caution in very elderly patients with CKD. Recent evidence suggests this population may experience higher rates of adverse outcomes including ICU admission, lactic acidosis, and need for renal replacement therapy, even with eGFR >30 mL/min/1.73 m² 6. Consider more conservative dosing and closer monitoring in this vulnerable group.
Lactic Acidosis Risk
While the absolute risk of metformin-associated lactic acidosis is very low (rare occurrence), risk increases substantially when eGFR <30 mL/min/1.73 m² 3, 7. The primary mechanism is reduced renal clearance leading to metformin accumulation. Contraindicate metformin in the presence of:
- Acute kidney injury
- Severe hepatic impairment
- Acute heart failure
- Respiratory insufficiency
- Sepsis or severe infection 2, 5
Guideline Consensus
The KDIGO 2022 guidelines provide the most comprehensive and authoritative recommendations for metformin dosing in CKD 1. These align closely with FDA labeling 2 and the 2025 ADA Standards of Care 3, which confirms metformin may be safely used when eGFR ≥30 mL/min/1.73 m². The key threshold of 30 mL/min/1.73 m² for discontinuation is consistent across all major guidelines and represents the point where risk clearly outweighs benefit.